S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:DVAX

Dynavax Technologies (DVAX) Stock Price, News & Analysis

$12.41
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$12.34
$12.52
50-Day Range
$11.70
$14.26
52-Week Range
$9.48
$15.15
Volume
1.53 million shs
Average Volume
2.01 million shs
Market Capitalization
$1.60 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00

Dynavax Technologies MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
101.5% Upside
$25.00 Price Target
Short Interest
Bearish
13.42% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.59
Upright™ Environmental Score
News Sentiment
0.13mentions of Dynavax Technologies in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$414,872 Sold Last Quarter
Proj. Earnings Growth
79.17%
From $0.24 to $0.43 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.54 out of 5 stars

Medical Sector

105th out of 938 stocks

Pharmaceutical Preparations Industry

40th out of 425 stocks

DVAX stock logo

About Dynavax Technologies Stock (NASDAQ:DVAX)

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

DVAX Stock Price History

DVAX Stock News Headlines

Dynavax Technologies: Still A Believer
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Dynavax Technologies: Still A Believer
Dynavax: Holding Firm Despite Its Missing Cash Cow
Dynavax: Holding Firm Despite Its Missing Cash Cow
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Dynavax Technologies Corporation (DVAX)
Dynavax Technologies Corp (DYF1.DU)
Dynavax’s Strong Financials and Promising Pipeline Secure Buy Rating
Dynavax Technologies: Q4 Earnings Insights
Here's what Wall Street expects from Dynavax Technologies's earnings
Dynavax Q4 2023 Earnings Preview
DVAX Jul 2024 18.000 call
DVAX Jan 2025 8.000 put
See More Headlines
Receive DVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/28/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:DVAX
CUSIP
26815810
Employees
408
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$25.00
High Stock Price Target
$28.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+101.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-6,390,000.00
Pretax Margin
-1.88%

Debt

Sales & Book Value

Annual Sales
$232.28 million
Book Value
$4.81 per share

Miscellaneous

Free Float
125,912,000
Market Cap
$1.61 billion
Optionable
Optionable
Beta
1.26

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

DVAX Stock Analysis - Frequently Asked Questions

Should I buy or sell Dynavax Technologies stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DVAX shares.
View DVAX analyst ratings
or view top-rated stocks.

What is Dynavax Technologies' stock price target for 2024?

4 Wall Street research analysts have issued twelve-month price objectives for Dynavax Technologies' shares. Their DVAX share price targets range from $20.00 to $28.00. On average, they expect the company's share price to reach $25.00 in the next year. This suggests a possible upside of 101.5% from the stock's current price.
View analysts price targets for DVAX
or view top-rated stocks among Wall Street analysts.

How have DVAX shares performed in 2024?

Dynavax Technologies' stock was trading at $13.98 at the beginning of the year. Since then, DVAX stock has decreased by 11.2% and is now trading at $12.41.
View the best growth stocks for 2024 here
.

Are investors shorting Dynavax Technologies?

Dynavax Technologies saw a increase in short interest in March. As of March 15th, there was short interest totaling 17,350,000 shares, an increase of 6.0% from the February 29th total of 16,370,000 shares. Based on an average daily volume of 1,960,000 shares, the short-interest ratio is presently 8.9 days.
View Dynavax Technologies' Short Interest
.

When is Dynavax Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our DVAX earnings forecast
.

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies Co. (NASDAQ:DVAX) released its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by $0.29. The biopharmaceutical company earned $108.27 million during the quarter, compared to analyst estimates of $77.30 million. Dynavax Technologies had a negative trailing twelve-month return on equity of 1.08% and a negative net margin of 2.75%. During the same period in the previous year, the firm earned ($0.15) earnings per share.

What is Eddie Gray's approval rating as Dynavax Technologies' CEO?

13 employees have rated Dynavax Technologies Chief Executive Officer Eddie Gray on Glassdoor.com. Eddie Gray has an approval rating of 59% among the company's employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 61.0% of employees surveyed would recommend working at Dynavax Technologies to a friend.

What other stocks do shareholders of Dynavax Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Matinas BioPharma (MTNB), First Solar (FSLR), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA).

Who are Dynavax Technologies' major shareholders?

Dynavax Technologies' stock is owned by a number of institutional and retail investors. Top institutional investors include Federated Hermes Inc. (8.79%), Vanguard Group Inc. (7.18%), Vanguard Group Inc. (7.17%), Chicago Capital LLC (4.40%), Dimensional Fund Advisors LP (3.12%) and Goldman Sachs Group Inc. (2.78%). Insiders that own company stock include Andrew A F Hack, David F Novack, David F Novack, Francis Cano, Justin Burgess, Robert Janssen and Ryan Spencer.
View institutional ownership trends
.

How do I buy shares of Dynavax Technologies?

Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DVAX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners